守正创新就是注入"活水"。要注重用现代科学解读中医药学原理，说明白、讲清楚中医药的疗效，推动 传统中医药和现代科学相结合、相促进，提升中医诊疗的现代化水平。运用国际通用的科学语言打开中 医药的"黑箱"，从"经验传承"走向"证据引领""数据说话"。 中医药是中华民族的瑰宝，也是世界人民的财富。世界需要中医药，中医药也将普惠世界。要坚定文化 自信，把中医药这一祖先留给我们的宝贵财富继承好、发展好、利用好，让中医药以新的姿态站到世界 医学舞台，增进人类健康福祉。 "生是中医人，死是中医魂。"在广东中医药博物馆，首届国医大师邓铁涛的名言令人动容。这位"铁杆 中医"的铮铮风骨，激励着一代又一代中医人踔厉奋发。 传承不泥古，创新不离宗。中医药是传统的，也是现代的；中医药是中国的，也是世界的。几千年来， 中医药不仅为中华民族繁衍昌盛作出卓越贡献，也对世界文明进步产生深远影响。中医药是我国独特的 卫生资源，需要代代守护、传承精华，也需要与时俱进、守正创新。 传承精华就是守住"根脉"。要遵循中医理论，善用中医思维，挖掘中医药宝库精华，发挥中医药在防病 治病中的独特优势。加强名老中医学术经验、老药工传统技艺传承，开展基于古代经典 ...

Core Viewpoint - The China Tong Ren Tang Group hosted the third Traditional Chinese Medicine Conference, showcasing its commitment to innovation and high-quality development in traditional Chinese medicine through a comprehensive display of products and research achievements [1] Product Matrix Presentation - Tong Ren Tang Technology Company presented over twenty major products, including Xihuang Pills, Jingzhi Niuhuang Jiedu Tablets, Liuwei Dihuang Pills, and others, covering categories such as anti-cancer, tonics, kidney diseases, and detoxification [3] - The company has developed a "six-dimensional product matrix" around its more than 200 traditional Chinese medicine products, ensuring that each product meets specific consumer needs [5] Rich Product Categories - The diverse range of health products, including Ejiao honey dates, herbal essence masks, and weight loss teas, attracted significant attention from medical professionals and researchers [5] - The company emphasizes the integration of traditional techniques with modern innovation, showcasing its commitment to quality and consumer health [5] Attention to Processing Techniques - The "intangible cultural heritage" exhibition highlighted the company's traditional processing techniques, which enhance the efficacy and adaptability of traditional Chinese medicine [6][8] - The processing methods, such as the treatment of herbs to improve absorption and reduce adverse effects, were demonstrated, showcasing the company's dedication to maintaining the integrity of traditional practices [10] Research and Innovation Driving Development - The company presented solid laboratory data on major products at the conference, enhancing consumer and client understanding of product efficacy [11] - Ongoing research includes clinical studies on various traditional Chinese medicine products, providing a scientific basis for their clinical applications [11]

Core Viewpoint - The article highlights the significant growth and market dominance of Suhexiang Wan, a traditional Chinese medicine, in the cardiovascular disease prevention and treatment sector, driven by policy support and modern clinical research [2][3]. Group 1: Market Performance - Suhexiang Wan's sales in urban public hospitals increased from 42.08 million yuan in 2020 to 558 million yuan in 2023, while retail sales in urban pharmacies rose from 232,000 yuan to 8.2 million yuan by 2024 [1]. - In the first half of 2024, Lei Yun Shang's Suhexiang Wan held a market share of approximately 75.15% in urban public medical institutions, with a retail growth rate of 236%, significantly outpacing competitors like Pian Zai Huang and Gui Ling Ji [1][3]. Group 2: Clinical and Retail Insights - Suhexiang Wan has been widely applied in clinical settings, covering nearly 3,000 hospitals and demonstrating effectiveness in emergency cases and cardiovascular disease prevention [4]. - The product's clear efficacy and modern adaptation have contributed to its retail success, contrasting with the slower growth of other traditional medicines like An Gong Niu Huang Wan and Gui Ling Ji, which saw declines in sales [5][6]. Group 3: Policy and Industry Trends - The Chinese government has intensified support for traditional Chinese medicine, with the "14th Five-Year Plan for Traditional Chinese Medicine Development" emphasizing the development and clinical application of classic formulas like Suhexiang Wan [6]. - The demand for cardiovascular health products is surging, with 81.7% of respondents in a health survey willing to invest more in health, indicating a growing market for traditional Chinese medicine [6][7]. Group 4: Competitive Landscape - The market for cardiovascular traditional Chinese medicine has expanded significantly, with total sales increasing from 5.216 billion yuan in 2017 to 10.083 billion yuan in 2024, nearly doubling [3]. - Suhexiang Wan's competitive edge is reinforced by its strong clinical evidence and market positioning, as it continues to capture a larger share of the growing demand for cardiovascular treatments [8].